US Food and Drug Administration (FDA) Commissioner Scott Gottlieb has made his support for increasing the availability of generic drugs very clear since assuming office in May.
A likely ally in his crusade will be the Federal Trade Commission (FTC), which has announced that it is to hold a workshop next month to discuss ways of ensuring competition thrives and continues to drive healthcare savings for Americans.
"In light of concerns about rising drug prices, it's critical we identify barriers that may prevent drugs from entering the market"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze